BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33195396)

  • 1. Functional Characterization of
    Boonen RACM; Vreeswijk MPG; van Attikum H
    Front Mol Biosci; 2020; 7():169. PubMed ID: 33195396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of 84 PALB2 variants of uncertain significance.
    Wiltshire T; Ducy M; Foo TK; Hu C; Lee KY; Belur Nagaraj A; Rodrigue A; Gomes TT; Simard J; Monteiro ANA; Xia B; Carvalho MA; Masson JY; Couch FJ
    Genet Med; 2020 Mar; 22(3):622-632. PubMed ID: 31636395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2.
    Boonen RACM; Rodrigue A; Stoepker C; Wiegant WW; Vroling B; Sharma M; Rother MB; Celosse N; Vreeswijk MPG; Couch F; Simard J; Devilee P; Masson JY; van Attikum H
    Nat Commun; 2019 Nov; 10(1):5296. PubMed ID: 31757951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair.
    Pulver EM; Mukherjee C; van de Kamp G; Roobol SJ; Rother MB; van der Gulden H; de Bruijn R; Lattanzio MV; van der Burg E; Drenth AP; Verkaik NS; Hahn K; Klarenbeek S; de Korte-Grimmerink R; van de Ven M; Pritchard CEJ; Huijbers IJ; Xia B; van Gent DC; Essers J; van Attikum H; Ray Chaudhuri A; Bouwman P; Jonkers J
    Cancer Res; 2021 Dec; 81(24):6171-6182. PubMed ID: 34548335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction.
    Caleca L; Catucci I; Figlioli G; De Cecco L; Pesaran T; Ward M; Volorio S; Falanga A; Marchetti M; Iascone M; Tondini C; Zambelli A; Azzollini J; Manoukian S; Radice P; Peterlongo P
    Front Oncol; 2018; 8():480. PubMed ID: 30410870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Missense PALB2 germline variant disrupts nuclear localization of PALB2 in a patient with breast cancer.
    Toh MR; Low CE; Chong ST; Chan SH; Ishak NDB; Courtney E; Kolinjivadi AM; Rodrigue A; Masson JY; Ngeow J
    Fam Cancer; 2020 Apr; 19(2):123-131. PubMed ID: 32048105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional assessment of missense variants of uncertain significance in the cancer susceptibility gene PALB2.
    Wu S; Qi L; Chen H; Zhang K; He J; Guo X; Shen L; Zhou Y; Zhong X; Zheng S; Zhou J; Chen Y
    NPJ Breast Cancer; 2022 Jul; 8(1):86. PubMed ID: 35853885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The p.Ser64Leu and p.Pro104Leu missense variants of PALB2 identified in familial pancreatic cancer patients compromise the DNA damage response.
    Zhang Y; Park JY; Zhang F; Olson SH; Orlow I; Li Y; Kurtz RC; Ladanyi M; Chen J; Toland AE; Zhang L; Andreassen PR
    Hum Mutat; 2021 Feb; 42(2):150-163. PubMed ID: 33169439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PALB2 Variants: Protein Domains and Cancer Susceptibility.
    Nepomuceno TC; Carvalho MA; Rodrigue A; Simard J; Masson JY; Monteiro ANA
    Trends Cancer; 2021 Mar; 7(3):188-197. PubMed ID: 33139182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
    Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
    Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.
    Rodrigue A; Margaillan G; Torres Gomes T; Coulombe Y; Montalban G; da Costa E Silva Carvalho S; Milano L; Ducy M; De-Gregoriis G; Dellaire G; Araújo da Silva W; Monteiro AN; Carvalho MA; Simard J; Masson JY
    Nucleic Acids Res; 2019 Nov; 47(20):10662-10677. PubMed ID: 31586400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway.
    Loke J; Pearlman A; Upadhyay K; Tesfa L; Shao Y; Ostrer H
    Hum Mol Genet; 2015 Jun; 24(11):3030-7. PubMed ID: 25652403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of
    Petitalot A; Dardillac E; Jacquet E; Nhiri N; Guirouilh-Barbat J; Julien P; Bouazzaoui I; Bonte D; Feunteun J; Schnell JA; Lafitte P; Aude JC; Noguès C; Rouleau E; Lidereau R; Lopez BS; Zinn-Justin S; Caputo SM;
    Mol Cancer Res; 2019 Jan; 17(1):54-69. PubMed ID: 30257991
    [No Abstract]   [Full Text] [Related]  

  • 14. Rates of Variants of Uncertain Significance Among Patients With Breast Cancer Undergoing Genetic Testing: Regional Perspectives.
    Abdel-Razeq H; Tamimi F; Abujamous L; Abdel-Razeq R; Abunasser M; Edaily S; Abdulelah H; Khashabeh RA; Bater R
    Front Oncol; 2022; 12():673094. PubMed ID: 35402282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.
    Toland AE; Andreassen PR
    J Med Genet; 2017 Nov; 54(11):721-731. PubMed ID: 28866612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline Missense Variants in
    Golubeva VA; Nepomuceno TC; Monteiro ANA
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31013702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers.
    Chevrier S; Richard C; Collot T; Mananet H; Arnould L; Boidot R
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.
    Guidugli L; Shimelis H; Masica DL; Pankratz VS; Lipton GB; Singh N; Hu C; Monteiro ANA; Lindor NM; Goldgar DE; Karchin R; Iversen ES; Couch FJ
    Am J Hum Genet; 2018 Feb; 102(2):233-248. PubMed ID: 29394989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
    Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
    J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer.
    Nakagomi H; Sakamoto I; Hirotsu Y; Amemiya K; Mochiduki H; Omata M
    Int J Clin Oncol; 2016 Apr; 21(2):270-275. PubMed ID: 26411315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.